BBX Logo Beta
本 IPO 暂未提供该语言版本,已显示英文内容。 [en]
TenNor Therap-B logo

TenNor Therap-B

06872 · HKEX
已上市

Dano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical product…

已上市

IPO 时间线

  1. 招股开始May 14
  2. 招股结束May 19
  3. 中签公布May 21
  4. 缴款日May 22
  5. 上市日May 22

基础资料

发行价

HKD 75.70

入场费

HKD 3,823.17

发行股数

8.86M

每手股数

50

总募资额

HKD 670.4M

估值市值

HKD 3.92B

公开发售比例

10.0%

国际配售比例

90.0%

业务介绍

Dano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical products to address unmet clinical needs in the fields of bacterial infections and bacterial metabolism‑related diseases.

募资用途

1、71.0% or approximately HK$395.7 million will be used for the research, development, registration filing and commercialisation of the Company’s core products;

2、7.0% or approximately HK$39.2 million will be used to fund the research and development of the oral formulation of TNP‑2092;

3、7.3% or approximately HK$40.9 million will be used for the research and development of other candidate products of the Company;

4、7.2% or approximately HK$40.2 million will be used for the construction of the Company’s own manufacturing plant;

5、7.5% or approximately HK$41.8 million will be used as working capital and for other general corporate purposes.

保荐人战绩对照

战绩数据正在更新中。

中介与文件

保荐人

  • 中信證券(香港)有限公司
  • 農銀國際融資有限公司

包销商

  • 中信里昂證券有限公司
  • 農銀國際證券有限公司
  • 華興證券(香港)有限公司
  • 富途證券國際(香港)有限公司
  • 老虎證券(香港)環球有限公司

招股书 PDF

招股书 PDF →

基石投资者

  • AMR Action Fund, L.P.
  • 华圆管理咨询(香港)有限公司
  • AMR Action Fund, SCSp
  • 东方资产管理(香港)有限公司
  • 骏升环球有限公司

Total

0

37.3% of placement

BBX 不参与本页所列任何 IPO 的配售流程。本页仅供信息参考,不构成投资建议。